19. L.G. Espinola, J. Beaucaire, A. Gottschalk, V.J. Caride, Radiolabeled liposomes as metabolic
and scanning tracers in mice. II. In-111 oxine compared with Tc-99 m DTPA, entrapped in
multilamellar lipid vesicles. J. Nucl. Med. 20(5), 434–440 (1979)
20. A.F. Turner, C.A. Presant, R.T. Proffitt, L.E. Williams, D.W. Winsor, J.L. Werner,
In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 166(3), 761–765 (1988)
21. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, R.G. Vile et al.,
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled
PEGylated liposomes. Clin. Cancer Res. 7(2), 243–254 (2001)
22. E.T. Dams, W.J. Oyen, O.C. Boerman, G. Storm, P. Laverman, P.J. Kok et al.,
99m
Tc-PEG
liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation.
J. Nucl. Med. 41(4), 622–630 (2000)
23. B.D. Williams, M.M. O’Sullivan, G.S. Saggu, K.E. Williams, L.A. Williams, J.R. Morgan,
Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann. Rheum.
Dis. 46(4), 314–318 (1987)
24. N. Li, Z. Yu, T.T. Pham, P.J. Blower, R. Yan, A generic
89
Zr labeling method to quantify the
in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography. Int.
J. Nanomedicine. 12, 3281–3294 (2017)
25. L.T. Lin, C.H. Chang, H.L. Yu, R.S. Liu, H.E. Wang, S.J. Chiu et al., Evaluation of the
therapeutic and diagnostic effects of PEGylated liposome-embedded
188
Re on human
non-small cell lung cancer using an orthotopic small-animal model. J. Nucl. Med. 55(11),
1864–1870 (2014)
26. M. Lingappa, H. Song, S. Thompson, F. Bruchertseifer, A. Morgenstern, G. Sgouros,
Immunoliposomal delivery of
213
Bi for alpha-emitter targeting of metastatic breast cancer.
Cancer Res. 70(17), 6815–6823 (2010)
27. P.J. Theodore, All About Albumin (Elsevier, Amsterdam, 1995)
28. K.M. Sand, M. Bern, J. Nilsen, H.T. Noordzij, I. Sandlie, J.T. Andersen, Unrav-eling the
interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol. 5, 682 (2015)
29. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46, 6387–6392 (1986)
30. C.R. Divgi, N.M. Lisann, S.D. Yeh, R.S. Benua, Technetium-99m albumin scintigraphy in
the diagnosis of protein-losing enteropathy. J. Nucl. Med. 27(11), 1710–2 (1986)
31. D.W. Nyman, K.J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M.
J. Hawkins, D.D. Von Hoff, Phase I and pharmacokinetics trial of ABI-007, a novel
nanoparticle formulation of paclitaxel in patients with advanced non-hematologic malignancies. J. Clin. Oncol. 23(31), 7785–7793 (2005)
32. A.M. Merlot, D.S. Kalinowski, D.R. Richardson, Unraveling the mysteries of serum
albumin-more than just a serum protein. Front Physiol. 5, 299 (2014)
33. R. Kloiber, B. Damtew, L. Rosenthall, A crossover study comparing the effect of particle size
on the distribution of radiocolloid in patients. Clin. Nucl. Med. 6(5), 204–206 (1981)
34. M.G. Persico, L. Lodola, F.E. Buroni, M. Morandotti, P. Pallavicini, C. Aprile,
99m Tc-human
serum albumin nanocolloids: particle sizing and radioactivity distribution. J. Label.
Comp. Radiopharm. 58(9), 376–382 (2015)
35. L. Tian, Q. Chen, X. Yi, G. Wang, J. Chen, P. Ning et al., Radionuclide I-131 labeled
Albumin-Paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of
cancer. Theranostics 7(3), 614–623 (2017)
36. O. Jacobson, D.O. Kiesewetter, X. Chen, Albumin-binding Evans Blue derivatives for
diagnostic imaging and production of long-acting therapeutics. Bioconjug. Chem. 27, 2239–
2247 (2016)
37. D.A. Tomalia, H. Baker, J.R. Dewald, M. Hall, G. Kallos, S. Martin, A new class of
polymers: starburst-dendritic macromolecules. Polym. J. 9(1), 117–132 (1985)
38. A.R. Menjoge, R.M. Kannan, D.A. Tomalia, Dendrimer-based drug and imaging conjugates:
design considerations for nanomedical applications. Drug Discov. Today. 15, 171–185 (2010)
5 Organic Nanomaterials: Liposomes, Albumin, Dendrimer …
121
and scanning tracers in mice. II. In-111 oxine compared with Tc-99 m DTPA, entrapped in
multilamellar lipid vesicles. J. Nucl. Med. 20(5), 434–440 (1979)
20. A.F. Turner, C.A. Presant, R.T. Proffitt, L.E. Williams, D.W. Winsor, J.L. Werner,
In-111-labeled liposomes: dosimetry and tumor depiction. Radiology 166(3), 761–765 (1988)
21. K.J. Harrington, S. Mohammadtaghi, P.S. Uster, D. Glass, A.M. Peters, R.G. Vile et al.,
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled
PEGylated liposomes. Clin. Cancer Res. 7(2), 243–254 (2001)
22. E.T. Dams, W.J. Oyen, O.C. Boerman, G. Storm, P. Laverman, P.J. Kok et al.,
99m
Tc-PEG
liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation.
J. Nucl. Med. 41(4), 622–630 (2000)
23. B.D. Williams, M.M. O’Sullivan, G.S. Saggu, K.E. Williams, L.A. Williams, J.R. Morgan,
Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann. Rheum.
Dis. 46(4), 314–318 (1987)
24. N. Li, Z. Yu, T.T. Pham, P.J. Blower, R. Yan, A generic
89
Zr labeling method to quantify the
in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography. Int.
J. Nanomedicine. 12, 3281–3294 (2017)
25. L.T. Lin, C.H. Chang, H.L. Yu, R.S. Liu, H.E. Wang, S.J. Chiu et al., Evaluation of the
therapeutic and diagnostic effects of PEGylated liposome-embedded
188
Re on human
non-small cell lung cancer using an orthotopic small-animal model. J. Nucl. Med. 55(11),
1864–1870 (2014)
26. M. Lingappa, H. Song, S. Thompson, F. Bruchertseifer, A. Morgenstern, G. Sgouros,
Immunoliposomal delivery of
213
Bi for alpha-emitter targeting of metastatic breast cancer.
Cancer Res. 70(17), 6815–6823 (2010)
27. P.J. Theodore, All About Albumin (Elsevier, Amsterdam, 1995)
28. K.M. Sand, M. Bern, J. Nilsen, H.T. Noordzij, I. Sandlie, J.T. Andersen, Unrav-eling the
interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front. Immunol. 5, 682 (2015)
29. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46, 6387–6392 (1986)
30. C.R. Divgi, N.M. Lisann, S.D. Yeh, R.S. Benua, Technetium-99m albumin scintigraphy in
the diagnosis of protein-losing enteropathy. J. Nucl. Med. 27(11), 1710–2 (1986)
31. D.W. Nyman, K.J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M.
J. Hawkins, D.D. Von Hoff, Phase I and pharmacokinetics trial of ABI-007, a novel
nanoparticle formulation of paclitaxel in patients with advanced non-hematologic malignancies. J. Clin. Oncol. 23(31), 7785–7793 (2005)
32. A.M. Merlot, D.S. Kalinowski, D.R. Richardson, Unraveling the mysteries of serum
albumin-more than just a serum protein. Front Physiol. 5, 299 (2014)
33. R. Kloiber, B. Damtew, L. Rosenthall, A crossover study comparing the effect of particle size
on the distribution of radiocolloid in patients. Clin. Nucl. Med. 6(5), 204–206 (1981)
34. M.G. Persico, L. Lodola, F.E. Buroni, M. Morandotti, P. Pallavicini, C. Aprile,
99m Tc-human
serum albumin nanocolloids: particle sizing and radioactivity distribution. J. Label.
Comp. Radiopharm. 58(9), 376–382 (2015)
35. L. Tian, Q. Chen, X. Yi, G. Wang, J. Chen, P. Ning et al., Radionuclide I-131 labeled
Albumin-Paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of
cancer. Theranostics 7(3), 614–623 (2017)
36. O. Jacobson, D.O. Kiesewetter, X. Chen, Albumin-binding Evans Blue derivatives for
diagnostic imaging and production of long-acting therapeutics. Bioconjug. Chem. 27, 2239–
2247 (2016)
37. D.A. Tomalia, H. Baker, J.R. Dewald, M. Hall, G. Kallos, S. Martin, A new class of
polymers: starburst-dendritic macromolecules. Polym. J. 9(1), 117–132 (1985)
38. A.R. Menjoge, R.M. Kannan, D.A. Tomalia, Dendrimer-based drug and imaging conjugates:
design considerations for nanomedical applications. Drug Discov. Today. 15, 171–185 (2010)
5 Organic Nanomaterials: Liposomes, Albumin, Dendrimer …
121